...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Development of oral CTL vaccine using a CTP-integrated Sabin 1 poliovirus-based vector system
【24h】

Development of oral CTL vaccine using a CTP-integrated Sabin 1 poliovirus-based vector system

机译：使用基于CTP的Sabin 1脊髓灰质炎病毒载体系统开发口服CTL疫苗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We developed a CTL vaccine vector by modification of the RPS-Vax system, a mucosal vaccine vector derived from a poliovirus Sabin 1 strain, and generated an oral CTL vaccine against HIV-1.A DNA fragment encoding a cytoplasmic transduction peptide (CTP) was integrated into the RPS-Vax system to generate RPS-CTP, a CTL vaccine vector. An HIV-1 p24 cDNA fragment was introduced into the RPS-CTP vector system and a recombinant poliovirus (rec-PV) named vRPS-CTP/p24 was produced. vRPS-CTP/p24 was genetically stable and efficiently induced Th1 immunity and p24-specific CTLs in immunized poliovirus receptor-transgenic (PVR-Tg) mice. In challenge experiments, PVR-Tg mice that were pre-immunized orally with vRPS-CTP/p24 were resistant to challenge with a lethal dose of p24-expressing recombinant vaccinia virus (rMVA-p24). These results suggested that the RPS-CTP vector system had potential for developing oral CTL vaccines against infectious diseases. (C) 2015 Elsevier Ltd. All rights reserved.
机译：我们通过修改RPS-Vax系统开发了CTL疫苗载体，这是一种从脊髓灰质炎病毒Sabin 1株衍生的粘膜疫苗载体，并产生了针对HIV-1的口服CTL疫苗。集成到RPS-Vax系统中以生成CPS疫苗载体RPS-CTP。将HIV-1 p24 cDNA片段引入RPS-CTP载体系统，并产生了名为vRPS-CTP / p24的重组脊髓灰质炎病毒（rec-PV）。 vRPS-CTP / p24具有遗传稳定性，可在免疫脊髓灰质炎病毒受体转基因（PVR-Tg）小鼠中有效诱导Th1免疫和p24特异性CTL。在攻击实验中，经vRPS-CTP / p24口服预免疫的PVR-Tg小鼠对致命剂量的表达p24的重组牛痘病毒（rMVA-p24）的攻击具有抗性。这些结果表明，RPS-CTP载体系统具有开发针对感染性疾病的口服CTL疫苗的潜力。 （C）2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号